4D Molecular Therapeutics, Inc.
$10.07
▼
-3.95%
2026-04-21 06:48:02
www.4dmoleculartherapeutics.com
NMS: FDMT
Explore 4D Molecular Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$535.53 M
Current Price
$10.07
52W High / Low
$12.34 / $2.88
Stock P/E
—
Book Value
$8.78
Dividend Yield
—
ROCE
-30.52%
ROE
-27.57%
Face Value
—
EPS
$-2.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
196
Beta
2.93
Debt / Equity
4.24
Current Ratio
9.39
Quick Ratio
9.39
Forward P/E
-2.54
Price / Sales
5.88
Enterprise Value
$119.57 M
EV / EBITDA
-0.79
EV / Revenue
1.4
Rating
Strong Buy
Target Price
$31.11
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 2. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 3. | AIM ImmunoTech Inc. | $0.49 | — | $3.99 M | — | 2638.91% | 251.38% | $19.74 / $0.51 | $-3.19 |
| 4. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 5. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 6. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 7. | Caris Life Sciences, Inc. | $21.24 | — | $5.98 B | — | 4.52% | -45.37% | $42.5 / $16.28 | $2.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 85.09 M | 0.09 M | 0.01 M | 0.01 M | 0 M | — |
| Operating Profit | 14.71 M | -61.19 M | -59.46 M | -53.62 M | -56.12 M | — |
| Net Profit | 19.4 M | -56.88 M | -54.66 M | -47.97 M | -49.67 M | — |
| EPS in Rs | 0.38 | -1.11 | -1.07 | -0.94 | -0.97 | -0.79 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 85.21 M | 0.04 M | 20.72 M | 3.13 M |
| Operating Profit | -159.55 M | -187.84 M | -112.87 M | -110.03 M |
| Net Profit | -140.11 M | -160.87 M | -100.84 M | -107.49 M |
| EPS in Rs | -2.74 | -3.15 | -1.98 | -2.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 566.71 M | 560.38 M | 339.89 M | 261.85 M |
| Total Liabilities | 61.05 M | 49.78 M | 32.06 M | 30.51 M |
| Equity | 505.66 M | 510.61 M | 307.83 M | 231.34 M |
| Current Assets | 413.13 M | 434.93 M | 296.59 M | 220.51 M |
| Current Liabilities | 43.98 M | 29.15 M | 18.95 M | 15.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -109.08 M | -134.59 M | -75.79 M | -86.69 M |
| Investing CF | -92.97 M | -302.44 M | 115.72 M | -17.05 M |
| Financing CF | 112.96 M | 337.25 M | 156.83 M | 3.08 M |
| Free CF | -109.62 M | -138.37 M | -78.56 M | -98.22 M |
| Capex | -0.54 M | -3.79 M | -2.77 M | -11.54 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -99.82% | 562.29% | — | — |
| Earnings Growth % | -59.53% | 6.19% | — | — |
| Profit Margin % | -434778.38% | -486.59% | -3435.41% | — |
| Operating Margin % | -507678.38% | -544.65% | -3516.52% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -489556.76% | -516.9% | -3392.52% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.